1. Home
  2. SID vs URGN Comparison

SID vs URGN Comparison

Compare SID & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Companhia Siderurgica Nacional S.A.

SID

Companhia Siderurgica Nacional S.A.

HOLD

Current Price

$0.91

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$37.79

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SID
URGN
Founded
1941
2004
Country
Brazil
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
2002
2016

Fundamental Metrics

Financial Performance
Metric
SID
URGN
Price
$0.91
$37.79
Analyst Decision
Strong Sell
Strong Buy
Analyst Count
1
7
Target Price
$1.40
$29.29
AVG Volume (30 Days)
5.6M
613.1K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$1.71
$129.09
Revenue Next Year
$1.58
$70.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.89
$12.89
52 Week High
$2.20
$37.88

Technical Indicators

Market Signals
Indicator
SID
URGN
Relative Strength Index (RSI) 26.81 78.88
Support Level N/A $18.58
Resistance Level $1.43 N/A
Average True Range (ATR) 0.05 1.75
MACD -0.02 0.46
Stochastic Oscillator 4.62 95.82

Price Performance

Historical Comparison
SID
URGN

About SID Companhia Siderurgica Nacional S.A.

Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations port concessions and fleets of road transport vehicles. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: